Abstract 4075
Background
Cancer causes loss of muscle mass, which is associated with a poor prognosis. Chemotherapy could also reduce muscle mass. We investigated changes of skeletal muscle mass during palliative chemotherapy and its association of treatment outcomes in patients with advanced gastric cancer (AGC).
Methods
This retrospective study consisted of 91 consecutive patients who underwent first line palliative chemotherapy in AGC. Skeletal muscle area was measured at the level of the third lumbar vertebra using computed tomography scans taken before and after chemotherapy. We assessed changes in skeletal muscle index (SMI), body mass index (BMI), and body weight and compared the chemotherapy response and survival according to the changes of body composition.
Results
In total 91 patients, median age was 64 years (range, 31-87 years). 75.4% of patients were male and 45.1% were sarcopenia at baseline. Mean decrease of SMI from pre-chemotherapy to post-chemotherapy was -5.4 ± 5.3 cm2/m2 (P < 0.001), mean decrease of BMI was -0.6 ± 1.9 kg/m2 (p = 0.002), and mean decrease of body weight was -1.8 ± 5.3 kg (P = 0.002). Mean decrease of SMI for patient with objective response was -4.4 ± 5.4 cm2/m2, mean decrease of SMI with stable disease was -6.0 ± 5.2 cm2/m2 and mean decrease of SMI with progression was -5.4 ± 5.2 cm2/m2. Response to chemotherapy was not associated with decrease in SMI (p = 0.491). In multivariable analysis, sarcopenia at baseline (HR, 1.959; 95% CI, 1.190 to 3.225, p = 0.008), decreased SMI (HR, 1.747; 95% CI, 1.042 to 2.929; p = 0.034) and poor ECOG score (HR, 1.902; 95% CI, 1.081 to 3.346; p = 0.026) were significant poor prognostic factors for survival.
Conclusions
Skeletal muscle mass decreased significantly during chemotherapy in patients with AGC. However, response to chemotherapy was not associated with decrease in skeletal muscle mass. The decreased SMI was a poor prognostic factor in patients with AGC during first line palliative chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4925 - Prognostic role of CD73 in metastatic Non Small Cell Lung Cancer according to the presence of driver alterations
Presenter: Giulia Galli
Session: Poster Display session 1
Resources:
Abstract
785 - JAK-STAT inhibitor overcomes interferon γ-reduced, NK cell-mediated cytotoxicity in non-small-cell lung cancer cells
Presenter: Riki Okita
Session: Poster Display session 1
Resources:
Abstract
2326 - Low LATS2 expression is associated with poor prognosis in non small cell lung cancer
Presenter: Si-hyong Jang
Session: Poster Display session 1
Resources:
Abstract
5960 - Application of ESCAT and OncoKB scales in Liquid biopsy (LB) in Advanced NSCLC patients (pts): Is it feasible and reliable?
Presenter: Michael McCusker
Session: Poster Display session 1
Resources:
Abstract
4855 - IDH1R132H mutation induces a less aggressive phenotype of glioma cells and affects the radiosensitivity by interacting with Wnt/β-catenin signaling
Presenter: Xuetao Han
Session: Poster Display session 1
Resources:
Abstract
2641 - Impact of Angiopoietin-2 on glioblastoma response to combined chemo-radiotherapy
Presenter: Charly Helaine
Session: Poster Display session 1
Resources:
Abstract
5743 - The Discovery of RNA-aptamers That Selectively Bind and Inhibit Glioblastoma Stem Cells by targeting EphA2
Presenter: Alessandra Affinito
Session: Poster Display session 1
Resources:
Abstract
4160 - Impact of tumor reoxygenation by nanoparticles on Tumor Associated Macrophages (TAMs)
Presenter: Aurélie Ferré
Session: Poster Display session 1
Resources:
Abstract
2474 - Prognostic significance of c-Rel/p50 heterodimer in the tumor microenvironment of uveal melanoma
Presenter: Seema Kashyap
Session: Poster Display session 1
Resources:
Abstract
1769 - Synergistic role of BAP1 and DNA damage response pathway in uveal melanoma and its prognostic significance.
Presenter: JAYANTI JHA
Session: Poster Display session 1
Resources:
Abstract